Efficacy and Safety of Ibuprofen/Loratadine Fixed-dose Combination Versus the Fixed-dose Administration of Monotherapy as Symptomatic Treatment for Patients With the Common Cold

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the drug combination of Ibuprofen/Loratadine versus Ibuprofen versus Loratadine as monotherapy for the symptomatic treatment of the common cold.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Agree to participate in the study and give written informed consent

• At least 6 points on the Jackson scale according to physical examination and questioning (sneezing, runny nose, nasal obstruction, sore throat, cough, headache, malaise, and chills).

• Symptoms associated with the common cold with maximum of 3 days since presentation

• Women of childbearing potential under a medically acceptable method of contraception

• At the discretion of the Principal Investigator (PI) or treating physician, treatment with the researching product is indicated and may present clinical benefit

Locations
Other Locations
Mexico
Laboratorio Silanes, S.A. de C.V.
RECRUITING
Mexico City
Contact Information
Primary
Jorge A Gonzalez, PhD
jogonzalez@silanes.com.mx
5254883785
Backup
Yulia Romero-Antonio, B.S.
yromero@silanes.com.mx
5254883785
Time Frame
Start Date: 2024-05-20
Estimated Completion Date: 2025-02-20
Participants
Target number of participants: 177
Treatments
Experimental: Ibuprofen + Loratadine
Administered orally (suspension), 5 mL twice a day, for 7 days.
Active_comparator: Ibuprofen
Administered orally (suspension), 20 mL, twice a day for 7 days.
Active_comparator: Loratadine
Administered orally (suspension), 5 mL, twice a day for 7 days
Related Therapeutic Areas
Sponsors
Leads: Laboratorios Silanes S.A. de C.V.

This content was sourced from clinicaltrials.gov